Ovarian cancer study explores Immune-Boosting drug combo
NCT ID NCT05053750
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times
Summary
This early-phase study tests whether adding zoledronic acid to standard chemotherapy and a targeted therapy can help women with ovarian cancer that has stopped responding to platinum-based treatment. The main goal is to see how the drug combo affects immune cells called macrophages in the tumor. Only 14 women are enrolled, so this is a small pilot to gather information, not a large-scale treatment test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.